安络化纤丸治疗乙肝后肝纤维化疗效的Meta分析

• 药品评价-循证医学研究 • 上一篇下一篇

安络化纤丸治疗乙肝后肝纤维化疗效的Meta分析

李金妮,董蕾,杨娟

西安交通大学第二附属医院消化内科,西安交通大学第二附属医院消化内科,西安交通大学第二附属医院消化内科

收稿日期:2016-03-29 修回日期:2016-03-29 出版日期:2016-06-25 发布日期:2016-06-25

Therapeutic Efficacy of Anluohuaxian Pill in Treatment of Hepatitis B-related Cirrhosis： a Meta-analysis

李金妮,董蕾 and 杨娟

The Second Affiliated Hospital of Xi'an Jiao Tong University,,The Second Affiliated Hospital of Xi'an Jiao Tong University

Received:2016-03-29 Revised:2016-03-29 Online:2016-06-25 Published:2016-06-25

摘要/Abstract

摘要： ［摘要］目的：系统评价安络化纤丸在临床中抗肝纤维化的疗效。方法：计算机检索PubMed、中国期刊全文数据库、中国科技期刊数据库(维普)和万方数字化期刊全文数据库，全面收集安络化纤丸治疗慢性乙型肝炎、肝硬化患者随机对照试验(randomized controlled trials， RCTs)。检索时间为2000年1月至2015年12月。对纳入试验根据Jadad评分标准进行质量评价，并采用RevMan 5.2软件进行Meta分析。结果：共纳入25篇随机对照试验，纳入研究对象2026例，其中试验组1075例，对照组962例，所有试验都被评为低质量试验。Meta分析结果显示相对对照组安络化纤丸可显著降低慢性乙型肝炎、肝硬化患者肝纤维化指标，其中透明质酸(HA)水平[MD=-91.88， 95% 可信区间(confidence interval，CI )(-110.08，-73.68)，P<0.00001]，层黏连蛋白(LN)水平[MD=-23.26，95%CI(-36.47，-10.06)，P=0.0006 ]，Ⅲ型前胶原(PCⅢ)水平[MD=-46.58，95%CI(-58.65，-34.52)，P<0.00001]，Ⅳ型胶原蛋白(Ⅳ-C)水平[MD=-35.00，95%CI(-46.20，-23.80)，P<0.00001]。结论：安络化纤丸对乙肝后肝纤维化具有较好的抗纤维化作用。

Abstract: [Abstract]Objective： To systematically evaluate the efficacy of anluohuaxian pill in treatment of hepatitis B-related cirrhosis. Methods： Randomized controlled trials (RCTs) on anluohuaxian pill in treatment of hepatitis B-related cirrhosis from Jan. 2000 to Dec. 2015 were retrieved through databases including PubMed， Chinese Journal Full-Text Database， VIP Database for Chinese Technical Periodicals and Wanfang Digital Journal Full-text Database. Then using RevMan 5.2 software to perform a Meta-analysis. Results： 25 RCTs were included， involving 2026 cases of hepatitis B-related cirrhosis (the experimental group： n=1075； the control group： n=962)， all trials were low quality. The results of the Meta-analysis showed that as compared with the control group， anluohuaxian pill significantly decreased the levels of hepatitis B-related cirrhosis. the levels of HA[MD=-91.88， 95%CI (-110.08，-73.68)，P<0.00001]， LN[MD=-23.26，95%CI(-36.47，-10.06)，P=0.0006 ]， PCⅢ [MD=-46.58，95%CI (-58.65，-34.52)，P<0.00001]， Ⅳ-C[MD=-35.00，95%CI (-46.20，-23.80)，P<0.00001]. Conclusion： Anluohuaxian pill has obvious effect on hepatic fibrosis.

李金妮,董蕾,杨娟. 安络化纤丸治疗乙肝后肝纤维化疗效的Meta分析[J]. .

李金妮,董蕾 and 杨娟. Therapeutic Efficacy of Anluohuaxian Pill in Treatment of Hepatitis B-related Cirrhosis： a Meta-analysis[J]. .